• Je něco špatně v tomto záznamu ?

The influence of apolipoprotein A5 T-1131C and apolipoprotein E common genetic variants on the levels of hemostatic markers in dyslipidemic patients

D. Novotny, D. Karasek, H. Vaverkova, L. Slavik,

. 2014 ; 436 (-) : 11-7. [pub] 20140509

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15032026

OBJECTIVES: The aim of this study was to evaluate the relationships of the T-1131C (rs662799) polymorphism variants of apolipoprotein A5 (Apo A5) gene and variants of apolipoprotein E (Apo E) gene common polymorphism (rs429358, rs7412) to selected hemostatic markers. STUDY DESIGN AND METHODS: We examined 590 asymptomatic dyslipidemic patients, subsequently divided into MetS+ (n=146) and MetS- (n=444) groups according to the criteria for identification of the metabolic syndrome (MetS). We compared variant frequencies and differences in levels of hemostatic markers according to Apo A5, Apo E and Apo A5/Apo E common variants. RESULTS: The -1131C Apo A5 minor variant was associated with elevated tissue plasminogen activator (tPA) in comparison to TT genotype (p<0.001), but not in the MetS+ group. The analysis of Apo A5/Apo E common variants in all subjects revealed that the presence of -1131C minor allele has always been associated with higher levels of tPA in comparison with T allele, regardless of Apo E genotype. Also the presence of minor Apo E2 allele led to elevated tPA concentrations in both T and C carriers. In addition, common -1131C/E2 variant was associated with the highest tPA levels. CONCLUSION: We demonstrated a remarkable association especially between the -1131C Apo A5 variant and increased tPA levels in asymptomatic dyslipidemic patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15032026
003      
CZ-PrNML
005      
20151009100942.0
007      
ta
008      
151005s2014 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.cca.2014.04.029 $2 doi
035    __
$a (PubMed)24815086
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Novotny, Dalibor $u Department of Clinical Biochemistry, University Hospital Olomouc, I.P. Pavlova 6, 775 20 Olomouc, Czech Republic. Electronic address: dalibor.novotny@fnol.cz.
245    14
$a The influence of apolipoprotein A5 T-1131C and apolipoprotein E common genetic variants on the levels of hemostatic markers in dyslipidemic patients / $c D. Novotny, D. Karasek, H. Vaverkova, L. Slavik,
520    9_
$a OBJECTIVES: The aim of this study was to evaluate the relationships of the T-1131C (rs662799) polymorphism variants of apolipoprotein A5 (Apo A5) gene and variants of apolipoprotein E (Apo E) gene common polymorphism (rs429358, rs7412) to selected hemostatic markers. STUDY DESIGN AND METHODS: We examined 590 asymptomatic dyslipidemic patients, subsequently divided into MetS+ (n=146) and MetS- (n=444) groups according to the criteria for identification of the metabolic syndrome (MetS). We compared variant frequencies and differences in levels of hemostatic markers according to Apo A5, Apo E and Apo A5/Apo E common variants. RESULTS: The -1131C Apo A5 minor variant was associated with elevated tissue plasminogen activator (tPA) in comparison to TT genotype (p<0.001), but not in the MetS+ group. The analysis of Apo A5/Apo E common variants in all subjects revealed that the presence of -1131C minor allele has always been associated with higher levels of tPA in comparison with T allele, regardless of Apo E genotype. Also the presence of minor Apo E2 allele led to elevated tPA concentrations in both T and C carriers. In addition, common -1131C/E2 variant was associated with the highest tPA levels. CONCLUSION: We demonstrated a remarkable association especially between the -1131C Apo A5 variant and increased tPA levels in asymptomatic dyslipidemic patients.
650    _2
$a dospělí $7 D000328
650    _2
$a apolipoproteiny A $x genetika $7 D001054
650    _2
$a apolipoproteiny E $x genetika $7 D001057
650    _2
$a asymptomatické nemoci $7 D058070
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a dyslipidemie $x krev $x genetika $x patofyziologie $7 D050171
650    _2
$a ženské pohlaví $7 D005260
650    12
$a hemostáza $7 D006487
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a jednonukleotidový polymorfismus $7 D020641
650    _2
$a tkáňový aktivátor plazminogenu $x krev $7 D010959
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Karasek, David $u 3rd Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, I.P. Pavlova 6, 775 20 Olomouc, Czech Republic.
700    1_
$a Vaverkova, Helena $u 3rd Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, I.P. Pavlova 6, 775 20 Olomouc, Czech Republic.
700    1_
$a Slavik, Ludek $u Department of Haemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, I.P. Pavlova 6, 775 20 Olomouc, Czech Republic.
773    0_
$w MED00009464 $t Clinica chimica acta; international journal of clinical chemistry $x 1873-3492 $g Roč. 436, č. - (2014), s. 11-7
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24815086 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20151009101129 $b ABA008
999    __
$a ok $b bmc $g 1092902 $s 915152
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 436 $c - $d 11-7 $e 20140509 $i 1873-3492 $m Clinica chimica acta $n Clin Chim Acta $x MED00009464
LZP    __
$a Pubmed-20151005

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...